SCHEMBL5093395

SCHEMBL5093395

CCOC(=O)c1c(Cc2c(C)nsc2C)sc2c1c(=O)n(C)c(=O)n2C(C)C

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC16A1 P53985 5/20 0.42
CYP2C9 P11712 3/20 0.38
CYP3A4 P08684 2/20 0.38
SLC16A3 O15427 1/20 0.38
LMNA P02545 3/20 0.34
POLB P06746 3/20 0.34
GAA P10253 2/20 0.34
ALDH1A1 P00352 5/20 0.34
HPGD P15428 4/20 0.34
MAPT P10636 3/20 0.34
NPSR1 Q6W5P4 2/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
PKM P14618 1/20 0.34
HTT P42858 1/20 0.34
CCR6 P51684 1/20 0.34
KDM4E B2RXH2 3/20 0.33
TSHR P16473 1/20 0.32
ABCB11 O95342 1/20 0.32
CYP1A2 P05177 1/20 0.31
CYP2C19 P33261 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5107028 0.80 LMNA (0.35) SLC16A1LMNAPOLBGAAALDH1A1
SCHEMBL5106237 0.79 SLC16A1 (0.41) SLC16A1CYP2C9CYP3A4SLC16A3LMNA
SCHEMBL5100042 0.79 SLC16A1 (0.43) SLC16A1CYP2C9CYP3A4SLC16A3LMNA
SCHEMBL5100047 0.79 SLC16A1 (0.41) SLC16A1CYP2C9CYP3A4SLC16A3LMNA
SCHEMBL5096933 0.78 SLC16A1 (0.49) SLC16A1LMNAPOLBGAAALDH1A1
SCHEMBL5139201 0.78 SLC16A1 (0.45) SLC16A1CYP2C9CYP3A4SLC16A3
SCHEMBL5138945 0.75 SLC16A1 (0.56) SLC16A1CYP2C9CYP3A4LMNAALDH1A1
SCHEMBL5097159 0.74 SLC16A1 (0.46) SLC16A1CYP2C9CYP3A4LMNAPOLB
SCHEMBL5097869 0.74 SLC16A1 (0.49) SLC16A1CYP2C9CYP3A4LMNAGAA
SCHEMBL5093441 0.74 SLC16A1 (0.45) SLC16A1POLBMAPTMEN1PABPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080214579-A1 THIENOPYRIMIDINEDIONES AND THEIR USE IN THE MODULATION OF AUTOIMMUNE DISEASE ASTRAZENECA AB (SE) 2008-09-04 US disclosed
US-7384951-B2 Thienopyrimidinediones and their use in the modulation of autoimmune disease ASTRAZENECA AB (SE) 2008-06-10 US disclosed
EP-1587812-B1 THIENOPYRIMIDINEDIONES AND THEIR USE IN THE MODULATION OF AUTOIMMUNE DISEASE ASTRAZENECA AB (SE) 2006-08-09 EP disclosed
US-20060052400-A1 Thienopyriminediones and their use in the modulation of autoimmune disease ASTRAZENECA AB (SE) 2006-03-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080214579-A1 THIENOPYRIMIDINEDIONES AND THEIR USE IN THE MODULATION OF AUTOIMMUNE DISEASE TPMT, TYMP, TYMS SLC16A1 3968/4885CYP2C9 419/4885CYP3A4 494/4885
US-20060052400-A1 Thienopyriminediones and their use in the modulation of autoimmune disease C5, HRH4, CYP2S1 SLC16A1 4250/4885CYP2C9 113/4885CYP3A4 77/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.